Top

Published in:

01-02-2016 | Letter to Editor

Is Pulmonary non-Tuberculous Mycobacterial Disease Linked with a High Burden of Latent Cytomegalovirus?

Authors: Fathiah S. Amran, Kyungchul Kim, Andrew Lim, Rachel Thomson, Silvia Lee, Grant Waterer, Patricia Price

Published in: Journal of Clinical Immunology | Issue 2/2016

Abstract

Cytomegalovirus (CMV) establishes lifelong infections with episodes of active replication. We hypothesized that recurrent CMV replication in older individuals may suppress protective immune responses to non-tuberculous mycobacteria (NTM) and so potentiate pulmonary disease. Accordingly, levels of antibodies to three CMV antigen preparations were higher in NTM patients than in age-matched controls. This did not reflect broad-spectrum B cell activation as total immunoglobulin levels were not equivalently increased.

Landolfo S, Gariglio M, Gribaudo G, Lembo D. The human cytomegalovirus. Pharmacol & Therapeut. 2003;98(3):269–97.CrossRef

Wallace DL, Masters JE, De Lara CM, Henson SM, Worth A, Zhang Y, et al. Human cytomegalovirus-specific CD8+ T-cell expansions contain long-lived cells that retain functional capacity in both young and elderly subjects. Immunology. 2011;132(1):27–38.PubMedCentralCrossRefPubMed

Campos C, Pera A, Sanchez-Correa B, Alonso C, Lopez-Fernandez I, Morgado S, et al. Effect of age and CMV on NK cell subpopulations. Exp Gerontol. 2014;54:130–7.CrossRefPubMed

Spencer JV, Lockridge KM, Barry PA, Lin G, Tsang M, Penfold ME, et al. Potent immunosuppressive activities of cytomegalovirus-encoded interleukin-10. J Virol. 2002;76:1285–92.PubMedCentralCrossRefPubMed

Gredmark S, Tilburgs T, Söderberg-Nauclér C. Human cytomegalovirus inhibits cytokine-induced macrophage differentiation. J Virol. 2004;78(19):10378–89.PubMedCentralCrossRefPubMed

Papatriantafyllou M Infection: the interferon paradox. Nat Rev Immunol. 2013;13:392–3.CrossRefPubMed

Thomson RM. Changing epidemiology of pulmonary nontuberculous mycobacteria infections. Emerg Infect Dis. 2010;16:1576.PubMedCentralCrossRefPubMed

Griffith DE, Aksamit T, Brown-Elliott BA, Catanzaro A, Daley C, Gordin F, et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Resp Crit Care. 2007;175:367–416.CrossRef

Lim A, Allison C, Price P, Waterer G. Susceptibility to pulmonary disease due to mycobacterium avium–intracellulare (MAC) complex may reflect low IL-17 and high IL-10 responses rather than Th1 deficiency. Cl Immunol. 2010;137:296–302.CrossRef

10.

Stone SF, Price P, Tay-Kearney M-L, French MA. Cytomegalovirus (CMV) retinitis immune restoration disease occurs during highly active antiretroviral therapy-induced restoration of CMV-specific immune responses within a predominant Th2 cytokine environment. J Infect Dis. 2002;185:1813–7.CrossRefPubMed

11.

Smed-Sörensen A, Moll M, Cheng T-Y, Loré K, Norlin A-C, Perbeck L, et al. IgG regulates the CD1 expression profile and lipid antigen-presenting function in human dendritic cells via FcγRIIa. Blood. 2008;111:5037–46.PubMedCentralCrossRefPubMed

12.

Isaacson M K, Juckem L K, Compton T. Virus entry and innate immune activation human cytomegalovirus. Shenk T E, Stinski M F, editors. Human Cytomegalovirus. Heidelberg, Germany: Springer; 2008.p. 85–100

13.

Zanten J, Giessen M, Voort L, Son W, Bij W, The TH. Cytomegalovirus-specific antibodies to an immediate early antigen and a late membrane antigen and their possible role in controlling secondary cytomegalovirus infection. Clin Exp Immunol. 1991;83:102–7.PubMedCentralCrossRefPubMed

14.

Khan N, Hislop A, Gudgeon N, Cobbold M, Khanna R, Nayak L, et al. Herpesvirus-specific CD8 T cell immunity in old age: cytomegalovirus impairs the response to a coresident EBV infection. J Immunol. 2004;173:7481–9.CrossRefPubMed

15.

Lawson CM, Grundy JE, Shellam GR. Antibody responses to murine cytomegalovirus in genetically resistant and susceptible strains of mice. J Gen Virol. 1988;69:1987–98.CrossRefPubMed

16.

Gianella S, Morris SR, Tatro E, Vargas MV, Haubrich RH, Daar ES, et al. Virologic Correlates of Anti-CMV IgG Levels in HIV-1 Infected Men. J Infect Dis. 2013:jit434.

17.

Almeida C-AM, Price P, French MA. Brief communication: immune activation in patients infected with HIV type 1 and maintaining suppression of viral replication by highly active antiretroviral therapy. AIDS Res Hum Retrov. 2002;18:1351–5.CrossRef

18.

Tan DB, Amran FS, Teo T-H, Price P, Moodley YP. Levels of CMV-reactive antibodies correlate with the induction of CD28null T cells and systemic inflammation in chronic obstructive pulmonary disease (COPD). Cell Mol Immunol. 2015; Jan 26. doi:10.1038/cmi.2015.04.PubMedCentral

19.

Kim K, Waterer G, Thomson R, Yang IA, Nashi N, Tan D, et al. Levels of anti-cytokine antibodies may be elevated in patients with pulmonary disease associated with non-tuberculous mycobacteria. Cytokine. 2014;66:160–3.CrossRefPubMed

Title: Is Pulmonary non-Tuberculous Mycobacterial Disease Linked with a High Burden of Latent Cytomegalovirus?
Authors: Fathiah S. Amran
Kyungchul Kim
Andrew Lim
Rachel Thomson
Silvia Lee
Grant Waterer
Patricia Price
Publication date: 01-02-2016
Publisher: Springer US
Published in: Journal of Clinical Immunology / Issue 2/2016
Print ISSN: 0271-9142
Electronic ISSN: 1573-2592
DOI: https://doi.org/10.1007/s10875-016-0233-1

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2016

An infant with ZAP-70 deficiency with disseminated mycobacterial disease

Autosomal Dominant Hyper IgE Syndrome – Treatment Strategies and Clinical Outcomes

Novel Vasoregulatory Aspects of Hereditary Angioedema: the Role of Arginine Vasopressin, Adrenomedullin and Endothelin-1

Life with a Primary Immune Deficiency: a Systematic Synthesis of the Literature and Proposed Research Agenda

Defective Leukocyte Adhesion and Chemotaxis Contributes to Combined Immunodeficiency in Humans with Autosomal Recessive MST1 Deficiency

Genetic, Cellular and Clinical Features of ICF Syndrome: a French National Survey

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials